CA2384081A1 - Recombinant microorganisms expressing an oligosaccharide receptor mimic - Google Patents

Recombinant microorganisms expressing an oligosaccharide receptor mimic Download PDF

Info

Publication number
CA2384081A1
CA2384081A1 CA002384081A CA2384081A CA2384081A1 CA 2384081 A1 CA2384081 A1 CA 2384081A1 CA 002384081 A CA002384081 A CA 002384081A CA 2384081 A CA2384081 A CA 2384081A CA 2384081 A1 CA2384081 A1 CA 2384081A1
Authority
CA
Canada
Prior art keywords
fwdarw
gal
beta
microorganism
glc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002384081A
Other languages
English (en)
French (fr)
Inventor
Adrienne Paton
Renato Morona
James Paton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADELAIDE RESEARCH and INNOVATION Pty Ltd
Women's and Children's Hospital
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2384081A1 publication Critical patent/CA2384081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA002384081A 1999-09-10 2000-09-09 Recombinant microorganisms expressing an oligosaccharide receptor mimic Abandoned CA2384081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ2757A AUPQ275799A0 (en) 1999-09-10 1999-09-10 Recombinant bacterium expressing an oligosaccharide receptor mimic
AUPQ2757 1999-09-10
PCT/IB2000/001349 WO2001019960A1 (en) 1999-09-10 2000-09-09 Recombinant microorganisms expressing an oligosaccharide receptor mimic

Publications (1)

Publication Number Publication Date
CA2384081A1 true CA2384081A1 (en) 2001-03-22

Family

ID=3816927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002384081A Abandoned CA2384081A1 (en) 1999-09-10 2000-09-09 Recombinant microorganisms expressing an oligosaccharide receptor mimic

Country Status (16)

Country Link
US (2) US6833130B1 (enExample)
EP (1) EP1214396A4 (enExample)
JP (1) JP2003514512A (enExample)
AP (1) AP2002002444A0 (enExample)
AU (1) AUPQ275799A0 (enExample)
BR (1) BR0013915A (enExample)
CA (1) CA2384081A1 (enExample)
HU (1) HUP0202863A3 (enExample)
IN (1) IN2002DE00287A (enExample)
MX (1) MXPA02002536A (enExample)
NZ (1) NZ517821A (enExample)
OA (1) OA12020A (enExample)
PL (1) PL364796A1 (enExample)
SK (1) SK3472002A3 (enExample)
WO (1) WO2001019960A1 (enExample)
ZA (1) ZA200201958B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
AU2003256329A1 (en) * 2002-06-27 2004-01-19 University Of Washington Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
WO2005089775A1 (en) * 2004-03-17 2005-09-29 Adelaide Research And Innovation Pty Ltd Treatment and prevention of enterotoxigenic escherichia coli diarrhoeas
CA2558635A1 (en) * 2004-03-17 2005-09-29 Glycofi, Inc. Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
US20070166306A1 (en) * 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
US8236538B2 (en) * 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
EP2265135B1 (en) 2008-03-14 2017-12-20 Nestec S.A. Synbiotic mixture
EP2116139A1 (en) * 2008-05-08 2009-11-11 Nestec S.A. Sialic acid to support brain health in the elderly
WO2009136298A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
JP2009288065A (ja) * 2008-05-29 2009-12-10 Keio Gijuku Ｓｈｉｇａｔｏｘｉｎ２ｅ及びＳｈｉｇａｔｏｘｉｎ２ｅに対する抗体の検出方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018015380A1 (en) 2016-07-18 2018-01-25 Philippe Ulsemer Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors
CN106226536B (zh) * 2016-08-01 2017-11-10 福建省产品质量检验研究院 一种沙门氏菌h抗原的位相变异试验方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN112575041B (zh) * 2019-09-30 2022-12-13 江南大学 一种混合碳源高效发酵生产phb的工程菌及其应用
EP4045082A1 (en) 2019-10-14 2022-08-24 Acaryon GmbH Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof
WO2021263105A1 (en) 2020-06-26 2021-12-30 University Of Massachusetts Anti-etec adhesin protein antibodies and methods of use
WO2022212714A1 (en) 2021-04-01 2022-10-06 Becton Dickinson And Company Methods for enhancing specificity and sensitivity of group a streptococcus immunoassay
EP4130258A1 (en) * 2021-08-02 2023-02-08 Evonik Operations GmbH Microorganisms displaying viral decoy receptors
CN117004670B (zh) * 2023-10-07 2023-12-15 中国科学院天津工业生物技术研究所 一种磺基转移酶及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
US5089479A (en) 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
JP2636042B2 (ja) 1989-04-10 1997-07-30 株式会社三光開発科学研究所 ４，４▲′′′▼―ジヒドロキシクォーターフェニル誘導体およびその製造方法
US5032519A (en) 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5595900A (en) 1990-02-14 1997-01-21 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
EP0553113B1 (en) 1990-08-02 1998-11-25 Antex Biologics, Inc. Adhesion receptors for pathogenic or opportunistic microorganisms
US5260380A (en) 1992-01-23 1993-11-09 The University Of Akron Self-reinforced composite and process for preparing same
JP3041840B2 (ja) 1992-02-24 2000-05-15 東洋紡績株式会社 新規なグリセロールデヒドロゲナーゼ、その製法及びその用途
MX9304638A (es) 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US5401723A (en) 1992-12-02 1995-03-28 Colgate-Palmolive Company Glycoconjugate inhibition of Streptococcus pyrogenes adhesion
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
JPH07258093A (ja) 1994-03-23 1995-10-09 Morinaga Milk Ind Co Ltd 神経成長因子様剤
US5665561A (en) 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5627163A (en) 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
AU6485496A (en) 1995-07-14 1997-02-18 Glycotech Corp. Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
US6069137A (en) 1996-03-11 2000-05-30 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
JP2997419B2 (ja) 1996-05-31 2000-01-11 雪印乳業株式会社 脳ガングリオシド含量減少抑制剤
JPH107575A (ja) 1996-06-21 1998-01-13 Synsorb Biotec Inc 細菌性赤痢の処置
JP4637976B2 (ja) 1996-07-17 2011-02-23 雪印乳業株式会社 腸内代謝改善剤
DE19640791A1 (de) 1996-10-02 1998-04-16 Syntesome Ges Fuer Medizinisch Glycokonjugate als Inhibitoren der viralen Zelladhäsion
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
WO2000070060A1 (en) * 1999-05-18 2000-11-23 University Of Iowa Research Foundation Production of complex carbohydrates
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic

Also Published As

Publication number Publication date
PL364796A1 (en) 2004-12-13
AP2002002444A0 (en) 2002-03-31
AUPQ275799A0 (en) 1999-10-07
WO2001019960A1 (en) 2001-03-22
NZ517821A (en) 2004-01-30
MXPA02002536A (es) 2003-07-21
SK3472002A3 (en) 2002-10-08
US6833130B1 (en) 2004-12-21
US20050250196A1 (en) 2005-11-10
HUP0202863A3 (en) 2006-07-28
EP1214396A1 (en) 2002-06-19
BR0013915A (pt) 2002-11-19
OA12020A (en) 2006-04-19
JP2003514512A (ja) 2003-04-22
EP1214396A4 (en) 2008-01-02
HUP0202863A2 (hu) 2002-12-28
IN2002DE00287A (enExample) 2007-03-02
ZA200201958B (en) 2003-05-28

Similar Documents

Publication Publication Date Title
US6833130B1 (en) Recombinant microorganisms expressing an oligosaccharide receptor mimic
US20240277824A1 (en) Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
Hu et al. Vi capsular polysaccharide: Synthesis, virulence, and application
US20230293657A1 (en) Vaccine
JP7121016B2 (ja) 抗原に対する防御免疫の誘導
EP3183003B1 (en) Methods for prevention and/or treatment of infection
Karjalainen et al. Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus
JP2017515455A (ja) フコシル化オリゴ糖の生産に使用するためのアルファ（１，２）フコシルトランスフェラーゼ・シンジーン
US7182954B1 (en) Prebiotic oligosaccharides via alternansucrase acceptor reactions
Kelly et al. Nutritional influences on interactions between bacteria and the small intestinal mucosa
Wray et al. Escherichia coli infections in farm
US6291435B1 (en) Treatment of diarrhea caused by enteropathogenic Escherichia coli
Paton et al. Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections
AU783536B2 (en) Recombinant microorganisms expressing an oligosaccharide receptor mimic
Clegg et al. Klebsiella pneumoniae
US20250381257A1 (en) Vaccine
Cote et al. Prebiotic oligosaccharides via alternansucrase acceptor reactions
Paton et al. Designer Probiotics and Enteric Cytoprotection
Miller Genetic and structural analysis of lipooligosaccharide synthesis genes (lsg's) in Haemophilus influenzae
Paton et al. Treatment and Prevention of Enteric Infections With Toxin-binding Probiotics
Caimano Characterization of sequences associated with the type 3 capsule locus in Streptococcus pneumoniae
Pourhossein Capsule expression in clinical Escherichia coli K5 strains: A biochemical and genetic analysis of the role of the KfiB protein
Lin The binding mechanism of Enterotoxigenic Escherichia coli (ETEC) to swine intestinal epithelia
WO2005089775A1 (en) Treatment and prevention of enterotoxigenic escherichia coli diarrhoeas

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued